Kailera Therapeutics, Inc. (NASDAQ:KLRA) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Analysts give Kailera Therapeutics a “Moderate Buy” consensus: Five of eight analysts rate the stock a buy, one rates it a strong buy, while the average 12-month price target is $42.75.
• Kailera shares opened at $18.32, with a $2.38 billion market capitalization, but the company recently reported a quarterly loss of $1.09 per share, missing the $0.74 consensus estimate.
• Wellington Management acquired 2.9 million shares worth approximately $64.3 million, representing about 2.25% of Kailera’s outstanding stock at the end of the latest reporting period.

Kailera Therapeutics, Inc. (NASDAQ:KLRA - Get Free Report) has earned an average recommendation of "Moderate Buy" from the eight brokerages that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $42.75.

A number of research analysts have recently issued reports on the company. Jefferies Financial Group started coverage on Kailera Therapeutics in a research report on Tuesday, May 12th. They set a "buy" rating and a $48.00 target price on the stock. TD Cowen initiated coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They set a "buy" rating and a $57.00 price objective for the company. Zacks Research raised shares of Kailera Therapeutics to a "hold" rating in a report on Wednesday, May 13th. Evercore assumed coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They issued an "outperform" rating on the stock. Finally, JPMorgan Chase & Co. started coverage on shares of Kailera Therapeutics in a research note on Tuesday, May 12th. They set an "overweight" rating and a $30.00 target price for the company.

Kailera Therapeutics Stock Up 2.7%

NASDAQ KLRA opened at $18.32 on Thursday. The firm has a market cap of $2.38 billion and a PE ratio of -0.01. The business has a 50-day simple moving average of $19.36. Kailera Therapeutics has a twelve month low of $16.39 and a twelve month high of $28.23.

Kailera Therapeutics (NASDAQ:KLRA - Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.35). As a group, equities analysts anticipate that Kailera Therapeutics will post -3.89 EPS for the current fiscal year.

Institutional Investors Weigh In On Kailera Therapeutics

An institutional investor recently bought a new stake in Kailera Therapeutics stock. Wellington Management Group LLP bought a new stake in shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 2,919,110 shares of the company's stock, valued at approximately $64,308,000. Wellington Management Group LLP owned about 2.25% of Kailera Therapeutics at the end of the most recent reporting period.

About Kailera Therapeutics

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source